Searchable abstracts of presentations at key conferences in endocrinology

ea0056p61 | Adrenal cortex (to include Cushing's) | ECE2018

Histopathological characteristics of lipid-poor adrenal adenomas

Vicennati Valentina , Casadio Elena , De Leo Antonio , Mosconi Cristina , Nanni Cristina , Selva Saverio , Zavatta Guido , Rinaldi Eleonora , Pagotto Uberto , Santini Donatella , Di Dalmazi Guido

Background: Up to 30% of incidentally-discovered adrenal masses are lipid-poor adenomas (LPA). The clinical significance of LPA is poorly understood. The aim of the study was to investigate histopathological features of LPA and their association with radiological parameters.Methods: A total of 39 patients with radiological evidence of LPA were included. LPA was defined as an adrenal mass with pre-contrast Hounsfield units (HU) ≧10, associated wit...

ea0093oc21 | Oral communication 3: Adrenal Tumors and Neuroendocrine Tumors | EYES2023

Identification of adrenocortical masses malignancy through radiomics: A pilot study

Tucci Lorenzo , Vara Giulio , Improta Ilaria , De Leo Antonio , Selva Saverio , Balacchi Caterina , Santini Donatella , Mosconi Cristina , Vicennati Valentina , Pagotto Uberto , Di Dalmazi Guido

Background: Adrenal lipid poor adenoma (LPA) and adrenocortical cancer (ACC) may overlap in computerized tomography (CT). Radiomics recently emerged as new tool for malignant behavior identification.Aim: To assess radiomics utility for identification of ACC and LPA in adrenocortical masses with unenhanced (UE) CT scan attenuation≥10 Hounsfield Unit (HU).Methods: We retrospectively enrolled 50 patients, 38 radiologically defin...

ea0081rc3.4 | Rapid Communications 3: Thyroid 1 | ECE2022

Are BRAF-TERT mutated differentiated thyroid cancers similar to other double mutated?

Colapinto Alessandra , Basso Cristina , Vicennati Valentina , Cavicchi Ottavio , Lodi Rizzini Elisa , Golemi Arber , Tabacchi Elena , Nannini Margherita , De Biase Dario , De Leo Antonio , Tallini Giovanni , Pagotto Uberto , Repaci Andrea

Introduction: Differentiated thyroid cancers (DTCs) carrying BRAF and TERT mutations are associated with high-risk clinicopathological features and poor prognosis. However, there are currently no studies comparing BRAF-TERT tumors to other double mutated DTCs.Aim: To verify whether BRAF-TERT mutated DTCs differ from other double mutated DTCs in terms of clinicopathological characteristics and outcome.Materials and Methods: 168 DTCs...

ea0081rc3.5 | Rapid Communications 3: Thyroid 1 | ECE2022

Impact of stimulated thyroglobulin and BRAF status in Stage I and ATA intermediate risk DTC

Basso Cristina , Colapinto Alessandra , Vicennati Valentina , Pagotto Uberto , Tallini Giovanni , De Leo Antonio , De Biase Dario , Lodi Rizzini Elisa , Cavicchi Ottavio , Nannini Margherita , Tabacchi Elena , Golemi Arber , Repaci Andrea

Introduction: There is no clear indication for radioiodine treatment (RAI) in patients affected by differentiated thyroid cancer (DTC) in Stage I and ATA intermediate risk, according to American Thyroid Association (ATA) guidelines.Purpose: Our aim is to evaluate whether integration of BRAF status and thyroglobulin TSH-stimulated at the time of RAI (A-HTg) could further improve accuracy of stratification, and therefore therapeutic management, in DTC pati...